American Injectables, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, announced strategic leadership appointments to position the company for continued growth in 2025 and beyond. These changes come at a crucial time in the pharmaceutical manufacturing industry, as demand for domestic production continues to rise. 

Travis Allen, who has been instrumental in American Injectables' development since its founding, has been appointed Chief Executive Officer and Board Director. Paul Campanelli, former CEO of Endo International and Par Pharmaceutical, will transition to the role of Executive Chairman, while Kimberlee Steele, Managing Director of North America at SHL Medical, joins as a new Board Member.

"This transition is the result of a focused strategy years in the making," said Allen. "Having been part of American Injectables from the start, I'm proud to lead a team that works shoulder-to-shoulder with our customers—navigating complexity, ensuring reliability, and driving execution from clinical to commercial."

Travis Allen brings a unique blend of scientific expertise, operational leadership, and business development acumen to his role. As a Pharm.D. with experience in both shop floor operations and entrepreneurship, he has played a pivotal part in growing sterile injectable capabilities—from leading business development in the 503B outsourcing space to founding and scaling a commercial sterile injectables facility. His deep understanding of both the technical and strategic aspects of the industry positions him to navigate challenges, drive value and meet the growing demand for high-quality, domestically produced sterile injectables.

The company's leadership is further enhanced by Campanelli's tenured sterile products expertise and Steele's 25-year track record in the pharmaceutical and medical device industries. While Campanelli has been serving on the board since March 2024, his proven expertise makes him an ideal candidate to help lead the board as Executive Chairman.

As a new board member, Steele brings valuable insights from her leadership roles at SHL Medical and Catalent, where she supported growth across multiple drug technologies, including biologics, injectable drug products, and cell and gene therapy.

"American Injectables' commitment to transparent partnership and customer focus aligns perfectly with where our industry needs to go," said Kimberlee Steele, newly appointed Board Member. "I'm excited to help guide the company through its next phase of growth."

These appointments come at a pivotal time for American Injectables, following its recent FDA approval and as the company continues to enhance its capabilities in sterile injectable manufacturing. The strengthened leadership team will focus on accelerating growth and driving operational excellence. With these developments, American Injectables is well-positioned to meet growing demands from the industry while maintaining the highest quality standards.